A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI 505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety assessed as Adverse Events, ECG, vital signs and clinical laboratory tests
Guido Tricot, MD, PhD, Prof.
University of Utah
United States: Food and Drug Administration
|University of Maryland, Greenebaum Cancer Center||Baltimore, Maryland 21201|
|University of Utah Health Sciences Center, Department of Medicine, Division of Hematology, Utah Blood and Marrow Transplant and Myeloma Program||Salt Lake City, Utah 84132-2408|